查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1548166

全球血友病治疗市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Hemophilia Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 378 Pages | 商品交期: 最快1-2个工作天内

价格

全球血友病治疗市场需求预计将从 2023 年的 173.2 亿美元达到近 298.2 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 6.22%。

血友病是一种罕见的遗传性疾病，其特征是血液无法正常凝固，导致受伤或手术后长时间出血。血友病治疗涉及旨在替代或增强血液中缺乏的凝血因子的疗法。这些治疗方法包括浓缩凝血因子，它可以从血浆中提取或透过重组 DNA 技术生产。此外，基因疗法有望透过纠正潜在的遗传缺陷来提供长期解决方案。血友病的有效管理对于预防和控制出血事件至关重要，从而提高患者的生活品质。

市场动态

血友病患病率不断上升，全球约有万分之一的人受到影响，推动了对有效血友病治疗方案的需求。重组因子疗法的进步和新型基因疗法的开发为改善患者治疗结果和提供治癒方法提供了重要机会。例如，基因疗法的最新创新在临床试验中显示出有希望的结果，为长期解决方案提供了潜力。此外，提高意识和更好的诊断能力有助于早期发现和治疗，进一步推动血友病治疗市场的成长。政府的支持性措施和研究资助也为先进疗法的持续开发和可近性提供了机会。然而，创新疗法的高成本和发展中地区的获取机会有限可能会限制血友病治疗市场的成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球血友病治疗市场的各个细分市场进行了包容性评估。血友病治疗产业的成长和趋势为本研究提供了整体方法。

市场区隔

血友病治疗市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

依疾病类型

  • A 型血友病（重度、中度、轻度）
  • 血友病 B（重度、中度、轻度）
  • 其他疾病类型

按产品分类

  • 重组凝血因子浓缩物（因子 Vill、因子 IX）
  • 血浆衍生凝血因子浓缩物（因子 Vill、因子 IX）
  • 延长半衰期产品（Factor Vill、Factor IX）
  • 去氨加压素
  • 抗纤维蛋白溶解剂
  • 基因治疗产品

按患者

  • 儿科（0 至 4、5 至 13、14 至 l8）
  • 成人（19 至 44、45 岁以上）

按治疗

  • 预防
  • 一经请求

透过治疗

  • 因子替代疗法
  • 非因子替代疗法

按药物类别

  • 加压素
  • 凝血因子

依给药途径

  • 可注射
  • 鼻喷剂
  • 口服

按最终用途

  • 医院
  • 诊所
  • 血友病治疗中心
  • 其他最终用户

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲血友病治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。血友病治疗市场的主要参与者包括拜耳公司、百健公司、Biotest AG（Grifols，SA）、BioMarin Pharmaceutical Inc、CSL Behring LLC、Ferring BV.、基因泰克公司（罗氏控股公司）、Kedrion SPA、诺和诺德A/S、Octapharma AG、辉瑞公司、赛诺菲 SA、瑞典 Orphan Biovitrum AB、武田製药有限公司。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：血友病治疗 - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按疾病类型分類的市场吸引力分析
    • 按产品分類的市场吸引力分析
    • 患者市场吸引力分析
    • 按处理方式进行的市场吸引力分析
    • 按治疗方法进行的市场吸引力分析
    • 按药品类别分類的市场吸引力分析
    • 按给药途径进行的市场吸引力分析
    • 按最终用途分類的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球血友病治疗市场分析：依疾病类型

  • 依疾病类型概述
  • 按疾病类型进行历史和预测资料分析
  • A 型血友病（重度、中度、轻度）
  • 血友病 B（重度、中度、轻度）
  • 其他疾病类型

第 6 章：全球血友病治疗市场分析：依产品

  • 概述（按产品）
  • 按产品分类的历史和预测资料分析
  • 重组凝血因子浓缩物（因子 Vill、因子 IX）
  • 血浆衍生凝血因子浓缩物（因子 Vill、因子 IX）
  • 延长半衰期产品（Factor Vill、Factor IX）
  • 去氨加压素
  • 抗纤维蛋白溶解剂
  • 基因治疗产品

第 7 章：全球血友病治疗市场分析：依患者分类

  • 患者概述
  • 患者的历史和预测数据分析
  • 儿科（0 至 4、5 至 13、14 至 l8）
  • 成人（19 至 44、45 岁以上）

第 8 章：全球血友病治疗市场分析：依治疗分类

  • 按治疗概述
  • 依处理方式进行历史与预测资料分析
  • 预防
  • 一经请求

第 9 章：全球血友病治疗市场分析：依治疗方法

  • 治疗概述
  • 按治疗进行历史和预测数据分析
  • 因子替代疗法
  • 非因子替代疗法

第 10 章：全球血友病治疗市场分析：依药物类别

  • 按药物类别概述
  • 按药物类别进行历史和预测数据分析
  • 加压素
  • 凝血因子

第 11 章：全球血友病治疗市场分析：依给药途径

  • 依给药途径概述
  • 按给药途径进行历史和预测资料分析
  • 可注射
  • 鼻喷剂
  • 口服

第 12 章：全球血友病治疗市场分析：依最终用途分类

  • 按最终用途分类的概述
  • 按最终用途分类的历史和预测资料分析
  • 医院
  • 诊所
  • 血友病治疗中心
  • 其他最终用户

第 13 章：全球血友病治疗市场分析：依地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区按国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲按国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 14 章：血友病治疗公司的竞争格局

  • 血友病治疗市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 15 章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • Bayer AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Biogen Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Biotest AG (Grifols SA)
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Takeda Pharmaceutical Company Limited
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • BioMarin Pharmaceutical Inc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • CSL Behring LLC
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Ferring BV.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Genentech Inc. (Roche Holding AG)
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Kedrion SPA
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Novo Nordisk A/S
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Octapharma AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Pfizer Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Sanofi SA
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Swedish Orphan Biovitrum AB
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

Product Code: VMR112115486

The global demand for Hemophilia Treatment Market is presumed to reach the market size of nearly USD 29.82 Billion by 2032 from USD 17.32 Billion in 2023 with a CAGR of 6.22% under the study period 2024-2032.

Hemophilia is a rare genetic disorder that features the inability of blood to clot properly, leading to prolonged bleeding after injuries or surgeries. Hemophilia treatment involves therapies designed to replace or enhance deficient clotting factors in the blood. These treatments include clotting factor concentrates, which can be derived from blood plasma or produced through recombinant DNA technology. Additionally, gene therapy is promising in providing a long-term solution by correcting the underlying genetic defect. Effective management of hemophilia is crucial for preventing and controlling bleeding episodes, thereby improving patients' quality of life.

MARKET DYNAMICS

The increasing prevalence of hemophilia, with approximately 1 in 10,000 individuals affected globally, drives the demand for effective hemophilia treatment options. Advances in recombinant factor therapies and the development of novel gene therapies offer significant opportunities to improve patient outcomes and provide a cure. For instance, recent innovations in gene therapy have demonstrated promising results in clinical trials, offering the potential for long-term solutions. Additionally, increasing awareness and better diagnostic capabilities contribute to early detection and treatment, further driving hemophilia treatment market growth. Supportive government initiatives and funding for research also provide opportunities for the continued development and accessibility of advanced therapies. However, the high cost of innovative therapies and limited access in developing regions may restrain hemophilia treatment market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Hemophilia Treatment. The growth and trends of Hemophilia Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Hemophilia Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disease Type

  • Hemophilia A (Severe, Moderate, Mild)
  • Hemophilia B (Severe, Moderate, Mild)
  • Other Disease Types

By Product

  • Recombinant Coagulation Factor Concentrates (Factor Vill, Factor IX)
  • Plasma-Derived Coagulation Factor Concentrates (Factor Vill, Factor IX)
  • Extended Half-Life Products (Factor Vill, Factor IX)
  • Desmopressin
  • Antifibrinolytic Agents
  • Gene Therapy Products

By Patient

  • Pediatric (0 To 4, 5 To 13, 14 to l8)
  • Adult (19 To 44, 45+)

By Treatment

  • Prophylaxis
  • On Demand

By Therapy

  • Factor Replacement Therapy
  • Non-Factor Replacement Therapy

By Drug Class

  • Vasopressin
  • Coagulation Factors

By Route of Administration

  • Injectable
  • Nasal Spray
  • Oral

By End-use

  • Hospitals
  • Clinics
  • Hemophilia Treatment Centers
  • Other End-User

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Hemophilia Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Hemophilia Treatment market include Bayer AG, Biogen Inc., Biotest AG (Grifols, S.A.), BioMarin Pharmaceutical Inc, CSL Behring LLC, Ferring BV., Genentech Inc. (Roche Holding AG), Kedrion S.P.A, Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi SA, Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Company Limited. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. HEMOPHILIA TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Disease Type
    • 3.7.2 Market Attractiveness Analysis By Product
    • 3.7.3 Market Attractiveness Analysis By Patient
    • 3.7.4 Market Attractiveness Analysis By Treatment
    • 3.7.5 Market Attractiveness Analysis By Therapy
    • 3.7.6 Market Attractiveness Analysis By Drug Class
    • 3.7.7 Market Attractiveness Analysis By Route of Administration
    • 3.7.8 Market Attractiveness Analysis By End-use
    • 3.7.9 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY DISEASE TYPE

  • 5.1. Overview By Disease Type
  • 5.2. Historical and Forecast Data Analysis By Disease Type
  • 5.3. Hemophilia A (Severe, Moderate, Mild) Historic and Forecast Sales By Regions
  • 5.4. Hemophilia B (Severe, Moderate, Mild) Historic and Forecast Sales By Regions
  • 5.5. Other Disease Types Historic and Forecast Sales By Regions

6. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY PRODUCT

  • 6.1. Overview By Product
  • 6.2. Historical and Forecast Data Analysis By Product
  • 6.3. Recombinant Coagulation Factor Concentrates (Factor Vill, Factor IX) Historic and Forecast Sales By Regions
  • 6.4. Plasma-Derived Coagulation Factor Concentrates (Factor Vill, Factor IX) Historic and Forecast Sales By Regions
  • 6.5. Extended Half-Life Products (Factor Vill, Factor IX) Historic and Forecast Sales By Regions
  • 6.6. Desmopressin Historic and Forecast Sales By Regions
  • 6.7. Antifibrinolytic Agents Historic and Forecast Sales By Regions
  • 6.8. Gene Therapy Products Historic and Forecast Sales By Regions

7. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY PATIENT

  • 7.1. Overview By Patient
  • 7.2. Historical and Forecast Data Analysis By Patient
  • 7.3. Pediatric (0 To 4, 5 To 13, 14 to l8) Historic and Forecast Sales By Regions
  • 7.4. Adult (19 To 44, 45+) Historic and Forecast Sales By Regions

8. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY TREATMENT

  • 8.1. Overview By Treatment
  • 8.2. Historical and Forecast Data Analysis By Treatment
  • 8.3. Prophylaxis Historic and Forecast Sales By Regions
  • 8.4. On Demand Historic and Forecast Sales By Regions

9. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY THERAPY

  • 9.1. Overview By Therapy
  • 9.2. Historical and Forecast Data Analysis By Therapy
  • 9.3. Factor Replacement Therapy Historic and Forecast Sales By Regions
  • 9.4. Non-Factor Replacement Therapy Historic and Forecast Sales By Regions

10. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY DRUG CLASS

  • 10.1. Overview By Drug Class
  • 10.2. Historical and Forecast Data Analysis By Drug Class
  • 10.3. Vasopressin Historic and Forecast Sales By Regions
  • 10.4. Coagulation Factors Historic and Forecast Sales By Regions

11. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 11.1. Overview By Route of Administration
  • 11.2. Historical and Forecast Data Analysis By Route of Administration
  • 11.3. Injectable Historic and Forecast Sales By Regions
  • 11.4. Nasal Spray Historic and Forecast Sales By Regions
  • 11.5. Oral Historic and Forecast Sales By Regions

12. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY END-USE

  • 12.1. Overview By End-use
  • 12.2. Historical and Forecast Data Analysis By End-use
  • 12.3. Hospitals Historic and Forecast Sales By Regions
  • 12.4. Clinics Historic and Forecast Sales By Regions
  • 12.5. Hemophilia Treatment Centers Historic and Forecast Sales By Regions
  • 12.6. Other End-User Historic and Forecast Sales By Regions

13. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 13.1. Regional Outlook
  • 13.2. Introduction
  • 13.3. North America Sales Analysis
    • 13.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 13.3.2 North America By Segment Sales Analysis
    • 13.3.3 North America By Country Sales Analysis
    • 13.3.4 United States Sales Analysis
    • 13.3.5 Canada Sales Analysis
    • 13.3.6 Mexico Sales Analysis
  • 13.4. Europe Sales Analysis
    • 13.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 13.4.2 Europe By Segment Sales Analysis
    • 13.4.3 Europe By Country Sales Analysis
    • 13.4.4 United Kingdom Sales Analysis
    • 13.4.5 France Sales Analysis
    • 13.4.6 Germany Sales Analysis
    • 13.4.7 Italy Sales Analysis
    • 13.4.8 Russia Sales Analysis
    • 13.4.9 Rest Of Europe Sales Analysis
  • 13.5. Asia Pacific Sales Analysis
    • 13.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 13.5.2 Asia Pacific By Segment Sales Analysis
    • 13.5.3 Asia Pacific By Country Sales Analysis
    • 13.5.4 China Sales Analysis
    • 13.5.5 India Sales Analysis
    • 13.5.6 Japan Sales Analysis
    • 13.5.7 South Korea Sales Analysis
    • 13.5.8 Australia Sales Analysis
    • 13.5.9 South East Asia Sales Analysis
    • 13.5.10 Rest Of Asia Pacific Sales Analysis
  • 13.6. Latin America Sales Analysis
    • 13.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 13.6.2 Latin America By Segment Sales Analysis
    • 13.6.3 Latin America By Country Sales Analysis
    • 13.6.4 Brazil Sales Analysis
    • 13.6.5 Argentina Sales Analysis
    • 13.6.6 Peru Sales Analysis
    • 13.6.7 Chile Sales Analysis
    • 13.6.8 Rest of Latin America Sales Analysis
  • 13.7. Middle East & Africa Sales Analysis
    • 13.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 13.7.2 Middle East & Africa By Segment Sales Analysis
    • 13.7.3 Middle East & Africa By Country Sales Analysis
    • 13.7.4 Saudi Arabia Sales Analysis
    • 13.7.5 UAE Sales Analysis
    • 13.7.6 Israel Sales Analysis
    • 13.7.7 South Africa Sales Analysis
    • 13.7.8 Rest Of Middle East And Africa Sales Analysis

14. COMPETITIVE LANDSCAPE OF THE HEMOPHILIA TREATMENT COMPANIES

  • 14.1. Hemophilia Treatment Market Competition
  • 14.2. Partnership/Collaboration/Agreement
  • 14.3. Merger And Acquisitions
  • 14.4. New Product Launch
  • 14.5. Other Developments

15. COMPANY PROFILES OF HEMOPHILIA TREATMENT INDUSTRY

  • 15.1. Top Companies Market Share Analysis
  • 15.2. Market Concentration Rate
  • 15.3. Bayer AG
    • 15.3.1 Company Overview
    • 15.3.2 Company Revenue
    • 15.3.3 Products
    • 15.3.4 Recent Developments
  • 15.4. Biogen Inc.
    • 15.4.1 Company Overview
    • 15.4.2 Company Revenue
    • 15.4.3 Products
    • 15.4.4 Recent Developments
  • 15.5. Biotest AG (Grifols S.A.)
    • 15.5.1 Company Overview
    • 15.5.2 Company Revenue
    • 15.5.3 Products
    • 15.5.4 Recent Developments
  • 15.6. Takeda Pharmaceutical Company Limited
    • 15.6.1 Company Overview
    • 15.6.2 Company Revenue
    • 15.6.3 Products
    • 15.6.4 Recent Developments
  • 15.7. BioMarin Pharmaceutical Inc
    • 15.7.1 Company Overview
    • 15.7.2 Company Revenue
    • 15.7.3 Products
    • 15.7.4 Recent Developments
  • 15.8. CSL Behring LLC
    • 15.8.1 Company Overview
    • 15.8.2 Company Revenue
    • 15.8.3 Products
    • 15.8.4 Recent Developments
  • 15.9. Ferring BV.
    • 15.9.1 Company Overview
    • 15.9.2 Company Revenue
    • 15.9.3 Products
    • 15.9.4 Recent Developments
  • 15.10. Genentech Inc. (Roche Holding AG)
    • 15.10.1 Company Overview
    • 15.10.2 Company Revenue
    • 15.10.3 Products
    • 15.10.4 Recent Developments
  • 15.11. Kedrion S.P.A
    • 15.11.1 Company Overview
    • 15.11.2 Company Revenue
    • 15.11.3 Products
    • 15.11.4 Recent Developments
  • 15.12. Novo Nordisk A/S
    • 15.12.1 Company Overview
    • 15.12.2 Company Revenue
    • 15.12.3 Products
    • 15.12.4 Recent Developments
  • 15.13. Octapharma AG
    • 15.13.1 Company Overview
    • 15.13.2 Company Revenue
    • 15.13.3 Products
    • 15.13.4 Recent Developments
  • 15.14. Pfizer Inc.
    • 15.14.1 Company Overview
    • 15.14.2 Company Revenue
    • 15.14.3 Products
    • 15.14.4 Recent Developments
  • 15.15. Sanofi SA
    • 15.15.1 Company Overview
    • 15.15.2 Company Revenue
    • 15.15.3 Products
    • 15.15.4 Recent Developments
  • 15.16. Swedish Orphan Biovitrum AB
    • 15.16.1 Company Overview
    • 15.16.2 Company Revenue
    • 15.16.3 Products
    • 15.16.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Disease Type (USD MN)
  • Hemophilia A (Severe, Moderate, Mild) Market Sales By Geography (USD MN)
  • Hemophilia B (Severe, Moderate, Mild) Market Sales By Geography (USD MN)
  • Other Disease Types Market Sales By Geography (USD MN)
  • Analysis By Product (USD MN)
  • Recombinant Coagulation Factor Concentrates (Factor Vill, Factor IX) Market Sales By Geography (USD MN)
  • Plasma-Derived Coagulation Factor Concentrates (Factor Vill, Factor IX) Market Sales By Geography (USD MN)
  • Extended Half-Life Products (Factor Vill, Factor IX) Market Sales By Geography (USD MN)
  • Desmopressin Market Sales By Geography (USD MN)
  • Antifibrinolytic Agents Market Sales By Geography (USD MN)
  • Gene Therapy Products Market Sales By Geography (USD MN)
  • Analysis By Patient (USD MN)
  • Pediatric (0 To 4, 5 To 13, 14 to l8) Market Sales By Geography (USD MN)
  • Adult (19 To 44, 45+) Market Sales By Geography (USD MN)
  • Analysis By Treatment (USD MN)
  • Prophylaxis Market Sales By Geography (USD MN)
  • On Demand Market Sales By Geography (USD MN)
  • Analysis By Therapy (USD MN)
  • Factor Replacement Therapy Market Sales By Geography (USD MN)
  • Non-Factor Replacement Therapy Market Sales By Geography (USD MN)
  • Analysis By Drug Class (USD MN)
  • Vasopressin Market Sales By Geography (USD MN)
  • Coagulation Factors Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Injectable Market Sales By Geography (USD MN)
  • Nasal Spray Market Sales By Geography (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Analysis By End-use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Clinics Market Sales By Geography (USD MN)
  • Hemophilia Treatment Centers Market Sales By Geography (USD MN)
  • Other End-User Market Sales By Geography (USD MN)
  • Global Hemophilia Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Hemophilia Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Hemophilia Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Disease Type
  • Market Attractiveness Analysis By Product
  • Market Attractiveness Analysis By Patient
  • Market Attractiveness Analysis By Treatment
  • Market Attractiveness Analysis By Therapy
  • Market Attractiveness Analysis By Drug Class
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By End-use
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Disease Type (USD MN)
  • Hemophilia A (Severe, Moderate, Mild) Market Sales By Geography (USD MN)
  • Hemophilia B (Severe, Moderate, Mild) Market Sales By Geography (USD MN)
  • Other Disease Types Market Sales By Geography (USD MN)
  • Global Market Analysis By Product (USD MN)
  • Recombinant Coagulation Factor Concentrates (Factor Vill, Factor IX) Market Sales By Geography (USD MN)
  • Plasma-Derived Coagulation Factor Concentrates (Factor Vill, Factor IX) Market Sales By Geography (USD MN)
  • Extended Half-Life Products (Factor Vill, Factor IX) Market Sales By Geography (USD MN)
  • Desmopressin Market Sales By Geography (USD MN)
  • Antifibrinolytic Agents Market Sales By Geography (USD MN)
  • Gene Therapy Products Market Sales By Geography (USD MN)
  • Global Market Analysis By Patient (USD MN)
  • Pediatric (0 To 4, 5 To 13, 14 to l8) Market Sales By Geography (USD MN)
  • Adult (19 To 44, 45+) Market Sales By Geography (USD MN)
  • Global Market Analysis By Treatment (USD MN)
  • Prophylaxis Market Sales By Geography (USD MN)
  • On Demand Market Sales By Geography (USD MN)
  • Global Market Analysis By Therapy (USD MN)
  • Factor Replacement Therapy Market Sales By Geography (USD MN)
  • Non-Factor Replacement Therapy Market Sales By Geography (USD MN)
  • Global Market Analysis By Drug Class (USD MN)
  • Vasopressin Market Sales By Geography (USD MN)
  • Coagulation Factors Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Injectable Market Sales By Geography (USD MN)
  • Nasal Spray Market Sales By Geography (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Global Market Analysis By End-use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Clinics Market Sales By Geography (USD MN)
  • Hemophilia Treatment Centers Market Sales By Geography (USD MN)
  • Other End-User Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.